News
MREO
0.3029
-0.85%
-0.0026
Mereo BioPharma Group Price Target Maintained With a $1.00/Share by BTIG
Dow Jones · 15h ago
Mereo BioPharma Group Price Target Maintained With a $3.00/Share by Needham
Dow Jones · 15h ago
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga · 1d ago
Analysts Offer Insights on Healthcare Companies: Mereo Biopharma Group Plc (MREO) and Kalaris Therapeutics (KLRS)
TipRanks · 1d ago
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga · 1d ago
Mereo BioPharma Licenses Alvelestat Rights To Sentynl Therapeutics
NASDAQ · 1d ago
Mereo Biopharma Grants Sentynl Rights to Alvelestat Therapy
TipRanks · 1d ago
Mereo BioPharma reports Q2 EPS (1c), consensus (1c)
TipRanks · 1d ago
Mereo BioPharma Group GAAP EPS of -$0.01 in-line
Seeking Alpha · 1d ago
Mereo BioPharma Group Q2 EPS $(0.01), Inline
Benzinga · 1d ago
Mereo BioPharma licenses alvelestat to Sentynl Therapeutics in the U.S.
TipRanks · 1d ago
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga · 1d ago
Mereo BioPharma Reports Second Quarter 2026 Financial Results and Provides Corporate Highlights
Barchart · 1d ago
Weekly Report: what happened at MREO last week (0803-0807)?
Weekly Report · 2d ago
Weekly Report: what happened at MREO last week (0727-0731)?
Weekly Report · 08/03 10:06
Weekly Report: what happened at MREO last week (0720-0724)?
Weekly Report · 07/27 10:09
Weekly Report: what happened at MREO last week (0713-0717)?
Weekly Report · 07/20 10:06
Weekly Report: what happened at MREO last week (0706-0710)?
Weekly Report · 07/13 10:08
Weekly Report: what happened at MREO last week (0629-0703)?
Weekly Report · 07/06 10:11
Weekly Report: what happened at MREO last week (0622-0626)?
Weekly Report · 06/29 10:07
More
Webull provides a variety of real-time MREO stock news. You can receive the latest news about Mereo Biopharma through multiple platforms. This information may help you make smarter investment decisions.
About MREO
Mereo BioPharma Group plc is a biopharmaceutical company focused on the development of therapeutics for rare diseases. The Company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD). In addition to the rare disease programs, it has two oncology product candidates in clinical development, which include Etigilimab, an IgG1 monoclonal antibody which binds to the human T-cell immunoreceptor with Ig and ITIM domains (TIGIT) receptor on immune cells to improve the activation and effectiveness of T-cell and NK cell antitumor activity and Navicixizumab is a bispecific antibody that inhibits delta-like ligand 4 (DLL4) and vascular endothelial growth factor (VEGF). Navicixizumab is developed for the treatment of late-line ovarian cancer.